In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

No signal for an increase in suicidal ideation or attempts associated with GLP-1 use was seen across subgroups stratified by sex, race and ethnicity, GLP-1 type, and diabetes status, as well as over a range of follow-up times up to 3 years, they noted in JAMA Pediatrics.

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts. But a new study involving more than 54,